Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2015 2
2016 2
2017 1
2018 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Pathophysiology and treatment of cardiac amyloidosis.
Gertz MA, et al. Nat Rev Cardiol 2015 - Review. Among authors: Sher T. PMID 25311231
Assessment of aspirated subcutaneous fat and bone-marrow biopsy samples verifies the diagnosis in 40-80% of patients, dependent on the type of amyloidosis. Mass spectroscopy can be used to determine the protein subunit and classify the disease as immunoglobulin light-chain amyloidosis or transthyretin-related amyloidosis associated with mutant or wild-type TTR (formerly known as familial amyloid cardiomyopathy and senile cardiac amyloidosis, respectively). ...
Assessment of aspirated subcutaneous fat and bone-marrow biopsy samples verifies the diagnosis in 40-80% of patients, dependent on the type …
Recent advances in the diagnosis and management of cardiac amyloidosis.
Sher T and Gertz MA. Future Cardiol 2014 - Review. PMID 24344669
The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. ...Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. ...
The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in thes …
Stem cell transplantation for immunoglobulin light chain amyloidosis.
Sher T and Gertz MA. Curr Probl Cancer 2017 - Review. PMID 28457657
Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). ...
Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidos
Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Sher T, et al. Biol Blood Marrow Transplant 2016 - Review. PMID 26475727 Free article.
Immunoglobulin light chain amyloidosis is the most common type of systemic amyloidosis. Hematopoietic stem cell transplantation (HCT) is an effective treatment option for AL however due to multi-organ involvement in this disease HCT is feasible in a minority of patients. ...In this review we discuss evolution of HCT and its typical application to a case of AL amyloidosis....
Immunoglobulin light chain amyloidosis is the most common type of systemic amyloidosis. Hematopoietic stem cell transplantatio …
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Sher T, et al. Clin Adv Hematol Oncol 2012. PMID 23187770
Immunoglobulin light-chain (AL) amyloidosis is a clonal plasma cell dyscrasia. Delay in diagnosis is the major hurdle in improving the outcomes of AL patients. ...
Immunoglobulin light-chain (AL) amyloidosis is a clonal plasma cell dyscrasia. Delay in diagnosis is the major hurdle in improving th …
First Report of Hereditary Lysozyme Amyloidosis in a South Asian Family.
Iqbal M, et al. Case Rep Hematol 2019. Among authors: Sher T. PMID 30881710 Free PMC article.
Lysozyme amyloidosis (ALys) is an exceedingly rare autosomal dominant hereditary type of systemic amyloidosis that can be misdiagnosed as other common types of systemic amyloidosis. ...
Lysozyme amyloidosis (ALys) is an exceedingly rare autosomal dominant hereditary type of systemic amyloidosis that can be misd …
Feedback